Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 04, 2022

BUY
$0.25 - $11.7 $7,043 - $329,647
28,175 Added 1056.43%
30,842 $6,000
Q2 2022

Aug 03, 2022

SELL
$0.3 - $1.31 $5,800 - $25,328
-19,335 Reduced 87.88%
2,667 $0
Q2 2021

Aug 12, 2021

SELL
$5.06 - $8.15 $7,326 - $11,801
-1,448 Reduced 6.17%
22,002 $116,000
Q1 2021

Apr 26, 2021

SELL
$6.24 - $9.58 $134,921 - $207,138
-21,622 Reduced 47.97%
23,450 $158,000
Q4 2020

Feb 02, 2021

BUY
$6.28 - $8.79 $283,052 - $396,182
45,072 New
45,072 $305,000
Q3 2020

Oct 14, 2020

SELL
$7.5 - $11.11 $128,422 - $190,236
-17,123 Closed
0 $0
Q2 2020

Jul 13, 2020

BUY
$8.33 - $13.79 $59,617 - $98,695
7,157 Added 71.81%
17,123 $179,000
Q1 2020

Apr 29, 2020

SELL
$3.83 - $8.79 $27,384 - $62,848
-7,150 Reduced 41.77%
9,966 $87,000
Q4 2019

Feb 05, 2020

BUY
$3.36 - $4.81 $13,933 - $19,947
4,147 Added 31.98%
17,116 $63,000
Q3 2019

Oct 15, 2019

BUY
$3.57 - $6.58 $41,665 - $76,795
11,671 Added 899.15%
12,969 $49,000
Q2 2019

Jul 26, 2019

BUY
$4.93 - $8.8 $6,399 - $11,422
1,298 New
1,298 $8,000
Q1 2019

Apr 18, 2019

SELL
$5.19 - $8.97 $3,959 - $6,844
-763 Closed
0 $0
Q4 2018

Jan 16, 2019

SELL
$4.29 - $9.94 $6,276 - $14,542
-1,463 Reduced 65.72%
763 $3,000
Q3 2018

Oct 23, 2018

BUY
$9.54 - $13.87 $21,236 - $30,874
2,226 New
2,226 $21,000
Q2 2018

Jul 30, 2018

SELL
$13.3 - $17.49 $944 - $1,241
-71 Closed
0 $0
Q1 2018

Apr 26, 2018

BUY
$12.26 - $18.98 $870 - $1,347
71 New
71 $1,000

Others Institutions Holding KALA

# of Institutions
1
Shares Held
1
Call Options Held
0
Put Options Held
0

About Kala Pharmaceuticals, Inc.


  • Ticker KALA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,464,160
  • Market Cap $8.67M
  • Description
  • Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...
More about KALA
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.